Tlr2/Tlr4 signaling pathway

Overview

The Tlr2/Tlr4 signaling pathway refers to the innate immune signaling network initiated by toll-like receptor 2 (TLR2) and toll-like receptor 4 (TLR4). These receptors are pattern-recognition receptors that detect microbial components and endogenous danger-associated molecules, then transmit signals through adaptor proteins such as myeloid differentiation factor 88 (MyD88) to activate downstream inflammatory programs, including nuclear factor-κB (NF-κB) and related cytokine pathways. In biomedical research, this pathway is widely studied as a central regulator of inflammation, immune activation, tissue injury, and host defense.

Because TLR2 and TLR4 can amplify proinflammatory cytokine production and interact with pathways such as the NLRP3 inflammasome, Gasdermin D, and caspase1, they are frequently investigated in models of neuroinflammation, autoimmune disease, metabolic injury, and vaccine adjuvant design. The pathway is also of interest in therapeutic modulation, where agents may suppress excessive TLR2/TLR4 signaling to reduce inflammation or, in other contexts, activate TLR4 to enhance immune responses.

Focus of Latest Publications

Recent publications have continued to place the Tlr2/Tlr4 signaling pathway at the center of inflammatory and immune-modulatory research across several disease models. In experimental autoimmune myocarditis, ginsenoside Rb1 was reported to downregulate proinflammatory cytokine expression via the Tlr2/Tlr4 signaling pathway in mice. In a separate in silico vaccine study against Chlamydia trachomatis serovar A, a multi-epitope construct was designed and evaluated for predicted binding to both TLR2 and TLR4, with immune simulations suggesting enhanced B- and T-cell responses and increased cytokine release upon repeated antigen exposure.

Multiple recent studies also linked TLR4-related signaling to intestinal inflammation and barrier dysfunction. In dextran sulfate sodium-induced colitis, donkey milk exosomes were shown to improve disease severity, strengthen barrier proteins, and reduce inflammatory cytokines; mechanistically, eca-let-7g directly targeted the TLR4 3'UTR to inhibit NF-κB signaling. Another colitis study using Perilla frutescens-derived nanovesicles reported reduced activation of the TLR4/MyD88/NF-κB axis alongside a shift from pro-inflammatory M1 to reparative M2 macrophages. In a related gut-liver axis model, alcohol and high-fat diet exposure aggravated colitis-associated liver injury, and transcriptomics revealed TLR4 pathway enrichment; TLR4 inhibition with TAK-242 improved survival and attenuated liver injury.

The pathway has also been examined in neuroinflammation, cardioprotection, and cancer-related immune regulation. In epileptic mice, sulforaphane reduced TLR4, MyD88, p-NF-κB, NLRP3, and caspase-1 expression, and the TLR4 inhibitor TAK-242 did not further enhance these effects, supporting a role for TLR4/NF-κB/NLRP3 signaling in the antiepileptic response. In myocardial ischemia/reperfusion injury, ginseng polysaccharides promoted intestinal Treg-derived exosomes whose surface HSP70 interacted with TLR4 on cardiomyocytes to trigger protective signaling and suppress cell death and inflammation. In lung adenocarcinoma, a disease-derived nanoplastic protein corona was reported to engage TLR4 through lysozyme and activate a PGRN-LXRα axis, promoting efferocytosis, M2 macrophage polarization, and reduced CD8+ T-cell infiltration. In cancer immunotherapy, chiral Mn3O4 nanoadjuvants showed enhanced uptake by dendritic cells partly through affinity for TLR4 and, when loaded with tumor antigens, activated both NLRP3 inflammasome and cGAS-STING pathways.

Recent work also expanded the range of TLR4-directed modulators. A computational vaccine design study identified a chimeric multi-epitope construct with strong predicted binding to TLR2 and TLR4, while a chemistry-focused study synthesized novel monosaccharide TLR4 agonists and found that one candidate, GAP214, induced higher IgG responses than a positive TLR4 agonist control after immunization. Together, these publications underscore ongoing interest in Tlr2/TLR4 signaling as both a mechanistic node in inflammatory disease and a therapeutic target or adjuvant interface in vaccination and immunomodulation.

Key Publications

• NEWJul Alcohol and High-Fat Diet Aggravate Colitis-Induced Liver Injury via Glucocorticoid/IL-6-SAA1 Axis in Mice. (Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2026, PMID 42385885): "Transcriptomics identified serum amyloid A1 (SAA1) as a highly upregulated acute-phase gene and revealed Toll-like receptor 4 (TLR4) pathway enrichment."
• NEWJul Donkey Milk Exosomes Protect Against Dextran Sulfate Sodium-Induced Colitis by Delivering Anti-Inflammatory miRNAs and Reshaping Gut Microbiota. (Journal of food science, 2026, PMID 42378030): "Mechanistically, eca‐let‐7g directly targeted TLR4 3'UTR to inhibit NF‐κB, while eca‐miR‐148a targeted NLRP3 3'UTR to suppress the NLRP3‐Caspase‐1‐IL‐18 axis."
• NEWJun Personalized Pathogenic Nanoplastic Coronas Orchestrate Efferocytosis-Driven Immune Evasion in Lung Adenocarcinoma. (ACS nano, 2026, PMID 42307976): "Mechanistically, corona-bound LYZ engaged Toll-like receptor 4 and activated a PGRN-LXRα signaling axis, thereby increasing lysosomal acidification-dependent efferocytosis, promoting M2 macrophage polarization, and reducing CD8+ T-cell infiltration."
• Jun Targeting TLR4-Depended NLRP3 Inflammasome: Sulforaphane's Mechanism in Suppressing Neuroinflammation and Seizures in Epileptic Mice. (Molecular nutrition & food research, 2026, PMID 42220202): "This study aimed to elucidate the role of the TLR4 pathway in the antiepileptic effects of sulforaphane (SFN)."
• May Computational design of a novel chimeric multi-epitope vaccine against chlamydia trachomatis serovar a to prevent trachoma. (Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026, PMID 42213354): "The final construct was well-stable and exhibited strong predicted binding with TLR2 and TLR4."
• Jun Remote mobilization of gut Tregs exosomes serves as nanoshuttles for targeted cardioprotection against ischemia/reperfusion injury by ginseng polysaccharides. (Pharmacological research, 2026, PMID 42061772): "where surface HSP70 interacted with TLR4 on cardiomyocytes, activating downstream protective signaling pathways and ultimately suppressing cardiomyocyte death and inflammatory responses."
• Jun Reprogramming anti-tumor immunity through both NLRP3 inflammasome and cGAS-STING pathways by chiral nanoadjuvants. (Science bulletin, 2026, PMID 41956854): "The L-type Mn3O4 nanoparticles (L-NPs) exhibit nearly twice the uptake rate into mouse bone marrow dendritic cells (BMDCs) compared to D-type Mn3O4 nanoparticles (D-NPs), thanks to a higher affinity for X-C motif chemokine ligand 1 (XCR1), cluster of differentiation 14 (CD14), and Toll-like receptor 4 (TLR4)."
• May Ginsenoside Rb1 downregulates proinflammatory cytokines expression via the Tlr2/Tlr4 signaling pathway in mice with experimental autoimmune myocarditis. (Biochemical and biophysical research communications, 2026, PMID 41905163): "Ginsenoside Rb1 downregulates proinflammatory cytokines expression via the Tlr2/Tlr4 signaling pathway in mice with experimental autoimmune myocarditis."
• Mar Exploring the mechanism of Bazheng San on rats with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) based on TLR4/NF-κB/NLRP3 signaling pathway. (Journal of ethnopharmacology, 2026, PMID 41881321): "Exploring the mechanism of Bazheng San on rats with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) based on TLR4/NF-κB/NLRP3 signaling pathway."
• Mar Orally deliverable Perilla frutescens-derived nanovesicles as natural bioactive nanocarriers for colon-targeted colitis therapy via microenvironment reprogramming. (Biomaterials advances, 2026, PMID 41875611): "they reprogrammed the immune microenvironment, accompanied by reduced activation of the TLR4/MyD88-NF-κB axis and a phenotypic shift from pro-inflammatory M1 to reparative M2 macrophages."